Novo Nordisk and AWS Launch AI Drug Discovery Hub to Accelerate Therapeutic Development

Novo Nordisk partners with Amazon Web Services to open an AI‑driven drug discovery hub that merges the pharmaceutical company’s research pipelines with AWS cloud‑based machine‑learning tools, aiming to speed early‑stage compound screening.

AWS engineers have relocated into Novo Nordisk’s laboratory space, working side‑by‑side with scientists to remove traditional coding bottlenecks, allowing bio‑discovery teams to run AI models directly on experimental data without separate software development steps.

The collaboration is expected to shorten the time needed to identify viable drug candidates, potentially lowering development costs and bringing new treatments to market faster, while showcasing a model for deep‑tech integration between pharma and cloud providers.

Industry analysts say the hub could serve as a template for other pharma‑cloud partnerships, highlighting how on‑site cloud engineers can accelerate data‑intensive research and reduce time from target identification to pre‑clinical testing.